Differences in Serum Luteinizing Hormone Measurements by Immunoradiometric Assay Induced by Kinetic Manipulation of Assay Conditions are Dependent on the Endocrine Milieu of Serum

1996 ◽  
Vol 33 (2) ◽  
pp. 107-111
Author(s):  
A O Olukoga ◽  
R Mitchell ◽  
L Walton ◽  
W R Robertson ◽  
I Laing
Keyword(s):  
Luteinizing Hormone ◽  
Polycystic Ovarian Syndrome ◽  
Immunoradiometric Assay ◽  
Serum Samples ◽  
Serum Luteinizing Hormone ◽  
Endocrine Status ◽  
Reference Preparation ◽  
Normal Men ◽  
Ovarian Syndrome ◽  
Assay Conditions

Divergent estimates for luteinizing hormone (LH) in individual serum samples may be given by different immunoassays. In order to investigate this phenomenom further, we have studied the effect of differences in assay kinetics within the same immunoradiometric assay (IRMA) configuration on LH measurement in sera from different endocrine states. Three pairs of monoclonal/polyclonal two-site IRMA systems for LH were developed from three LH monoclonal antibodies and a common polyclonal anti-human chorionic gonadotrophin. For IRMA systems a short and long assay, which were different only with respect to the incubation time (1/2 h and overnight respectively), of the labelled monoclonal first antibody were performed. The IRMAs were all standardized against the LH international reference preparation 68/40. LH concentrations were measured by all the IRMAs in sera obtained from normal men ( n = 11) and from women with polycystic ovarian syndrome (PCO; n = 13). In normal men, there were no differences in LH estimates between the short and the long assays of the three IRMA systems, and the ratios of long to short assays were similar for all the systems. However, in PCO there were significant differences between short and long assays and the ratios of long to short assays were different for the IRMA systems. These results indicate that kinetic differences between IRMAs of the same antibody configuration can be associated with differences in measured LH concentrations, depending on the endocrine status of the sera studied. As LH glycoform patterns are known to differ between normal men and PCO, the observed changes in LH estimates may be due to the different glycoform composition.

scholarly journals The effect of baseline serum luteinizing hormone levels on follicular development, ovulation, conception and pregnancy outcome in infertile patients with polycystic ovarian syndrome

2017 ◽  
Vol 7 (1) ◽  
pp. 318
Author(s):  
Deepa Shanmugham ◽  
R. K. Vidhyalakshmi ◽  
Shivamurthy H. M.
Keyword(s):  
Luteinizing Hormone ◽  
Pregnancy Outcome ◽  
Polycystic Ovarian Syndrome ◽  
Follicular Development ◽  
Baseline Serum ◽  
Serum Luteinizing Hormone ◽  
Serum Lh ◽  
The Mean ◽  
Infertile Patients ◽  
Ovarian Syndrome

Background: Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorder in infertile women. Raised tonic levels of luteinizing hormone (LH) is one of the main endocrinological disturbances in PCOS patients. Objective of present study was to evaluate the effect of baseline serum luteinizing hormone levels on follicular development, ovulation and conception and pregnancy outcome in infertile patients with PCOS.Methods: This is a prospective study conducted on 50 consecutive infertile patients with PCOS. Baseline Day 2 serum luteinizing hormone concentration was done in selected patients. Ovulation induction was done with clomiphene citrate 100 mg from Day 3 to Day 7 of the cycle. Then patients were monitored for follicular development, ovulation, conception and early pregnancy loss.Results: The mean age of the patients is 25±3.6 yrs. The average duration of infertility is 5.4 yrs (2-10). The mean basal serum LH concentration in patients who ovulated was significantly low (5.6 IU) in comparison with patients who did not ovulate (10.1 IU).  The mean basal serum LH concentration in patients who conceived was 3.9 IU in comparison with patients who did not conceive (5.9 IU) which was statistically significant (p=0.04).  Out of 15 patients who conceived, 3 patients (20%) had early pregnancy loss.Conclusions: Tonic hyper secretion of LH results in premature oocyte maturation, causing the problems with fertilization and miscarriage. Inappropriately raised LH appears to have deleterious effects on the pregnancy outcome.

scholarly journals Role of Anti-mullerian Hormone (AMH), As A Prediction of Clinical Pregnancy Outcome in Women with Polycystic Ovarian Syndrome with Sub Fertility

2018 ◽  
Vol 9 (1) ◽  
pp. 3-5
Author(s):  
Ashia Khatun ◽  
Afroza Kutubi ◽  
Khairun Nahar ◽  
Israt Jahan ◽  
Hasina Begum ◽  
...  
Keyword(s):  
Polycystic Ovarian Syndrome ◽  
Polycystic Ovary ◽  
Clinical Pregnancy ◽  
Age Group ◽  
Serum Samples ◽  
Ovary Syndrome ◽  
Randomized Sampling ◽  
Ovarian Syndrome ◽  
Good Linear Correlation

Background: Anti-mullerian hormone (AMH) in largely expressed throughout folliculogenisis (by granulosa cells in ovarian follicles) but highest in pre-antral and small antral steges (<4mm) drameter of development.Objective: To analyse the usefulness of plasma anti-mullerian hormone (AMH) measurement as a test for assessing ovarian reserve in Polycystic ovary syndrome with sub fertility,Methodology: Women with PCOS and sub fertility, were included in this study with age group 18-35yrs. This Prospetive cohort study done in 30 cases in ShSMC with purposive randomized sampling, from January 2015 to December 2015. Serum, plasma & for evaluation of PCOS, preferably TV-USG was done.Result: In this study we analyze 30 serum samples from patient aged between 18-35 years and transvaginal ultrasonography was done simultaneously. Mean age group of my patient was 25.2±4.7 years which correlates with AMH level in PCOS which is statistically significant (p<0.001). Mean level of AMH is 5.7±4.9 mg/ml which is also correlate with transvaginal USG scan with the feature of PCOS (p<.0.001). More than 50% woman presents with features of subfertility with PCOS and 46.7% are normal ovaries. Mean menstrual day 7.6 (4-12 days) which have a good linear correlation with irregularities of menstrual cycle and PCOS (p<0.05).Conclusion: To conclude AMH appears to have a major inhibiting role during folliculogenesis, which may contribute to anovulation in PCOS. The reason for the raised AMH in PCOS may give clues as to the mechanism os anovulation.J Shaheed Suhrawardy Med Coll, June 2017, Vol.9(1); 3-5

CLOMIPHENE CITRATE IN MEN: INCREASE OF CORTISOL, LUTEINIZING HORMONE, TESTOSTERONE AND STEROID-BINDING GLOBULINS

1972 ◽  
Vol 53 (2) ◽  
pp. 261-276 ◽  
Author(s):  
J. C. MARSHALL ◽  
D. C. ANDERSON ◽  
C. W. BURKE ◽  
A. GALVAO-TELES ◽  
T. RUSSELL FRASER
Keyword(s):  
Luteinizing Hormone ◽  
Plasma Cortisol ◽  
Specific Binding ◽  
Clomiphene Citrate ◽  
Normal Subjects ◽  
Sex Hormone Binding Globulin ◽  
Total Cortisol ◽  
Serum Luteinizing Hormone ◽  
Steroid Binding ◽  
Normal Men

SUMMARY The effects of clomiphene citrate were studied in nine normal men, in three patients with partial panhypopituitarism, and in four patients with isolated gonadotrophin deficiency. The administration of this drug to the normal subjects in a dosage of 3 mg/kg/day for 10 days resulted in a mean rise in serum luteinizing hormone (LH) of 107%, in plasma 17β-hydroxyandrogens (17-OHA) of 114%, and in plasma total cortisol of 86%. The rise of testosterone concentration in normal subjects was associated with a doubling of the non-protein bound fraction, and also with increased binding of testosterone to sex hormone-binding globulin (SHBG). In contrast, plasma non-protein bound and urinary unconjugated cortisol remained unchanged. The percentage of plasma cortisol not bound to protein fell, indicating that the rise in total plasma cortisol was secondary to increased protein binding. This was confirmed by finding increased binding of both cortisol and testosterone to their specific binding globulins at 1 °C, due apparently to increased concentrations of SHBG and corticosteroid-binding globulin after clomiphene administration. All the responses to clomiphene were prevented by simultaneous administration of fluoxymesterone in two normal subjects. All the hypopituitary patients showed no rise of LH, 17-OHA or cortisol. The hypogonadotrophic patients, however, showed a normal total cortisol rise. It is suggested that clomiphene has two actions. First, it interferes with the hypothalamic feed-back mechanisms for testosterone, resulting in increased LH secretion, and secondly it has an oestrogen-like effect in stimulating production of steroid-binding globulins.

Sign in / Sign up

Export Citation Format

Share Document